LGALS3 and glioblastoma: Consistent with our expectations, extensive experiments showed that the combination of an HDAC inhibitor and an LGALS3 inhibitor had a significant synergistic effect in the treatment of MES GBM, which was able to simultaneously block HDAC7-driven intrinsic tumour cell signalling and re-programme the suppressive TME.